Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 21 to 30 of 921

TitleReference numberPublishedLast updated
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatmentTA1159
Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinomaTA1160
Sotatercept for treating pulmonary arterial hypertensionTA1161
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancerTA1158
Givinostat for treating Duchenne muscular dystrophy in people 6 years and overTA1157
Osimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapyTA1156
Rozanolixizumab for treating antibody-positive generalised myasthenia gravisTA1155
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesityTA1152
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatmentTA1153
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal)TA1154

Results per page

  1. 10
  2. 25
  3. 50
  4. All